Key result
Adding omega-3 fatty acids to statin therapy cuts major coronary events by ~19%.
Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: The recent availability of a concentrated prescription omega-3 fatty acid preparation provides physicians with an additional anti-dyslipidemic agent at a time when limitations of statin therapy in dyslipidemic high-risk patients are recognized. This review examines the evidence supporting the use of omega-3 fatty acid treatment in dyslipidemic states. RECENT FINDINGS: There is now considerable evidence that omega-3 fatty acid treatment at the prescription strength of 4 g/day effectively and safely lowers triglyceride levels and increases low-density lipoprotein size, as well as affecting high-density lipoprotein metabolism. Similar effects have been noted in patients treated with statins, and add-on prescription omega-3 fatty acid therapy significantly increases the proportion of statin-treated dyslipidemic patients reaching their non-high-density lipoprotein cholesterol goals. In addition to past studies showing a cardioprotective effect of low-dose omega-3 fatty acid treatment against sudden death, a recent controlled clinical trial showed that 1.8 g of omega-3 fatty acid in statin-treated patients reduced major coronary events by 19% compared with statin plus placebo treatment. SUMMARY: Omega-3 fatty acid treatment should be considered in patients with severe hypertriglyceridemia as well as in high-risk patients with an atherogenic lipoprotein phenotype.
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (2008) conducted a review in Dyslipidemia. Prescription omega-3 fatty acid vs. Statin plus placebo was evaluated on Triglyceride lowering and major coronary events (19% reduction). Prescription omega-3 fatty acids at 4 g/day lower triglycerides, and 1.8 g added to statin therapy reduced major coronary events by 19% versus statin plus placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: